Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 ,inter alia, to consider and approve to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price and related payment mechanism, rights entitlement ratio, the record date and timing of the Rights Issue

22nd September, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers Plot No. C/1, G Block, Dalal Street, Fort Bandra–Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Maharashtra, India Symbol: NATCOPHARM Scrip Code: 524816 Dear Sirs/Madam(s), Subject: Prior intimation of the meeting of the Board of Directors of Natco Pharma Limited (the “Company”) to be held on 25th September, 2026 This is further to our intimation on the outcome of the meeting of the Board of Directors of the Company (“Board”) dated 9th September, 2026, wherein the issue of equity shares of face value of ₹2 each of the Company (“Rights Equity Shares”), by way of a rights issue for an amount not exceeding ₹1,300 crores (“Rights Issue”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws, was approved. This is to inform you that a meeting of the Board of Directors will be held on Friday, 25th September, 2026, inter alia, to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price and related payment mechanism, rights entitlement ratio, the record date and timing of the Rights Issue. This intimation is issued in terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Please further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time-to-time TRADING WINDOW for dealing in the securities of the Company by the Designated person(s), Employee(s), connected persons and their immediate relatives will be closed from 23rd September, 2026 till 48 hours after the intimation of the Outcome of the Board Meeting to the Stock Exchanges by the Company. We request you to take the aforesaid on record. Thanking you, Yours faithfully, For and on behalf of Natco Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer